Stem Cell Therapeutics Provides Corporate Update
13 Enero 2014 - 6:00AM
Marketwired
Stem Cell Therapeutics Provides Corporate Update
TORONTO, ONTARIO--(Marketwired - Jan 13, 2014) - Stem Cell
Therapeutics Corp. (TSX-VENTURE:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related
therapeutics, today provided the following six-month corporate
update:
- Pilot non-human primate tolerability studies have been
completed using SIRPaFc, Stem Cell Therapeutics' proprietary CD47
antagonist. Three separate human SIRPaFc proteins, possessing
different Fc regions with varying levels of effector function, were
evaluated in a repeat-dose regimen in cynomolgus macaques. Safe
dosing levels, substantially above the anticipated human
therapeutic dose, were established for each drug candidate. Greater
tolerability was observed to correlate with decreasing effector
function. Anemia and thrombocytopenia were the primary adverse
events observed, which in most cases were asymptomatic and
reversible. These studies, while preliminary in nature, provided
firm support for moving the SIRPaFc program forward into the next
development phase. In parallel with conducting the manufacturing
activities and toxicology studies typically associated with the
IND-enabling phase of drug development, the company will
significantly amplify its preclinical efficacy studies. This will
be critical in order to uncover the full potential of this
promising immune checkpoint inhibitor and to expand its use in the
treatment of both solid and liquid tumors.
- Preclinical SIRPaFc efficacy data in an acute myeloid leukemia
xenograft model was recently reported at the 55th Annual Meeting of
the American Society of Hematology (ASH). SIRPaFc was shown to
promote potent anti-leukemic responses at low doses. When combined
with the non-human primate tolerability data, this indicates a wide
therapeutic window. For details on the ASH presentation please
consult our website at www.stemcellthera.com.
- On December 13, 2013, the company completed a $33 million
private placement, principally with participation from experienced
U.S. healthcare institutional investors.Importantly, this
substantial financing, one of the largest by a
Canadianbiopharmaceutical company last year, was primarily driven
by the strength and promise of the SIRPaFc technology. Its proceeds
will allow the company to execute an optimal development program
over the next three years, which will include manufacturing, formal
toxicology testing, as well as clinical studies in cancer
patients.
- Dosing in the investigator-driven Phase I multicenter
dose-escalation study (50mg- 350mg) with tigecycline in patients
with relapsed or refractory acute myeloid leukemia (AML) is nearing
completion. Dosing has advanced to the 350mg cohort, a dose level
that greatly exceeds the 100mg dose approved for anti-infective use
and is well within the range of doses that have demonstrated
anti-cancer activity in published preclinical studies. Patient
recruitment has been slowed by the submission of a protocol
amendment. The cost of this study has been covered by the academic
sponsor. As the exclusive licensee of this technology, the company
continues to monitor the progress of the trial and anticipates its
completion in 2014. Following a thorough evaluation of the clinical
data and the program's commercial potential the company will decide
on an appropriate path forward.
About Stem Cell
Therapeutics:
Stem Cell
Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and
groundbreaking Canadian stem cell research, the company is
supported by established links to a group of prominent Toronto
academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research
hubs. The Company has two premier preclinical programs, SIRPaFc and
a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the
host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is
a fully human monoclonal antibody that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. SCT's clinical stage programs
include the recently in-licensed program focused on the structure
of tigecycline, which is currently being evaluated in a
multi-centre Phase I study in patients with acute myeloid leukemia
(AML), as well as TTI-1612, a non- cancer stem cell asset that
recently completed a 28-patient Phase I trial in interstitial
cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com
Caution Regarding
Forward-Looking Information:
This press release
may contain forward-looking statements, which reflect SCT's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include changing market
conditions; the successful and timely completion of pre-clinical
and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development
risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks
detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.comProActive
CapitalJeff RamsonInvestor Contact+1
646-863-6519jramson@proactivecapital.comProActive CapitalKirin
SmithInvestor Contact+1 646-863-6519ksmith@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sunvest Minerals Corp (TSX Venture Exchange): 0 recent articles
Más de Stem Cell Therapeutics Corp. Artículos de Noticias